~ Buy the QSYMIA (phentermine hydrochloride; topiramate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR QSYMIA

All Clinical Trials for QSYMIA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00796367 ↗	A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)	Completed	Medpace, Inc.	Phase 3	2008-12-01	The purpose of this study is to evaluate the long-term safety and efficacy of VI-0521 compared to placebo for the treatment of overweight and obesity in adults who have completed study OB-303 (NCT00553787) at selected study sites. This is an extension study of protocol OB-303 (NCT00553787).
NCT00796367 ↗	A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)	Completed	VIVUS, Inc.	Phase 3	2008-12-01	The purpose of this study is to evaluate the long-term safety and efficacy of VI-0521 compared to placebo for the treatment of overweight and obesity in adults who have completed study OB-303 (NCT00553787) at selected study sites. This is an extension study of protocol OB-303 (NCT00553787).
NCT01834404 ↗	Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 4	2013-04-01	Our overall goal is to determine the effect of Phentermine and Topiramate ER on gastric emptying, gastric accommodation, satiety, and satiation in obese participants.
NCT01834404 ↗	Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients	Completed	Mayo Clinic	Phase 4	2013-04-01	Our overall goal is to determine the effect of Phentermine and Topiramate ER on gastric emptying, gastric accommodation, satiety, and satiation in obese participants.
NCT02229214 ↗	Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects	Completed	VIVUS, Inc.	Phase 4	2014-08-01	The main purpose of this study is measure the effect of VI-0521 on kidney function. Specifically, glomerular filtration rate (GFR) will be measured at baseline, after 4 weeks of study treatment, and after an additional 4 weeks of off-treatment recovery.

Clinical Trial Conditions for QSYMIA

Condition Name

Condition Name for QSYMIA
Intervention	Trials
Obesity	12
Binge Eating Disorder	2
Adolescent Obesity	1
Polycystic Ovary Syndrome	1

Condition MeSH

Condition MeSH for QSYMIA
Intervention	Trials
Obesity	10
Overweight	5
Feeding and Eating Disorders	2
Pediatric Obesity	2

Clinical Trial Locations for QSYMIA

Trials by Country

Trials by Country for QSYMIA
Location	Trials
United States	13
Korea, Republic of	6

Trials by US State

Trials by US State for QSYMIA
Location	Trials
Minnesota	5
Ohio	3
Oklahoma	1
Louisiana	1
California	1

Clinical Trial Progress for QSYMIA

Clinical Trial Phase

Clinical Trial Phase for QSYMIA
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	3
Phase 2	5

Clinical Trial Status

Clinical Trial Status for QSYMIA
Clinical Trial Phase	Trials
Completed	8
Recruiting	4
Not yet recruiting	3

Clinical Trial Sponsors for QSYMIA

Sponsor Name

Sponsor Name for QSYMIA
Sponsor	Trials
VIVUS, Inc.	4
Mayo Clinic	3
Lindner Center of HOPE	2

Sponsor Type

Sponsor Type for QSYMIA
Sponsor	Trials
Other	12
Industry	9
NIH	1